patients with steady vital signs and affected by combined somnipathy at the early stage of stroke were divided into three groups according to the date of admission:the experimental group(Group E)and the control groups(Group C1 and Group C2).The rehabilitation programs to all patients are the same,except the somnipathy,(1) patients of Group E were adopted the method of acupuncture and moxibustion coupled with taping and pressing their ear acupuncture points to improve their quality of sleep,(2) patients of Group C1 were asked to administer orally the traquilizers,and (3) no interference was conducted to the patients of Group C2.After 8 weeks of treatment,it is found that,(1) the speed of recovery of the motor function of the patients of both Group E and Group C1 is faster than that of Group C2 (P<0.01).(2) The total sleeping hours of Group E is significantly compared with that of Group C1(P<0.05).This shows that the long-term effects of the acupuncture therapy on sleep are superior to that of the tranquilizer.It suggests that the acupuncture therapy is an improtant method to treat the sequelae and syndrome of stroke.

Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with strong contagiousness, high susceptibility and long incubation period. cell entry by SARS-CoV-2 requires the binding between the receptor-binding domain of the viral spike protein and the cellular angiotensin-converting enzyme 2 (ACE2). Here, we briefly reviewed the mechanisms underlying the interaction between SARS-CoV-2 and ACE2, and summarized the latest research progress on SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies, so as to better understand the development process and drug research direction of COVID-19. This review may facilitate understanding the development of neutralizing antibody drugs for emerging infectious diseases, especially for COVID-19.
Angiotensin-Converting Enzyme 2 ; Antibodies, Monoclonal ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 ; Humans ; Peptidyl-Dipeptidase A/metabolism* ; Protein Binding ; SARS-CoV-2 ; Single-Domain Antibodies ; Spike Glycoprotein, Coronavirus/metabolism*